These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7747708)

  • 1. Evaluation of the combination of vinblastine and quinidine in patients with metastatic renal cell carcinoma. A phase I study.
    Agarwala SS; Bahnson RR; Wilson JW; Szumowski J; Ernstoff MS
    Am J Clin Oncol; 1995 Jun; 18(3):211-5. PubMed ID: 7747708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma.
    Warner E; Tobe SW; Andrulis IL; Pei Y; Trachtenberg J; Skorecki KL
    Am J Clin Oncol; 1995 Jun; 18(3):251-6. PubMed ID: 7747714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vinblastine in metastatic renal cell carcinoma: EORTC phase II trial 30882. The EORTC Genitourinary Group.
    Fosså SD; Droz JP; Pavone-Macaluso MM; Debruyne FJ; Vermeylen K; Sylvester R
    Eur J Cancer; 1992; 28A(4-5):878-80. PubMed ID: 1524914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
    Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL
    Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma.
    Motzer RJ; Lyn P; Fischer P; Lianes P; Ngo RL; Cordon-Cardo C; O'Brien JP
    J Clin Oncol; 1995 Aug; 13(8):1958-65. PubMed ID: 7636536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of renal cell carcinoma with alpha (human leukocyte) interferon and vinblastine in combination: a phase I-II trial.
    Figlin RA; deKernion JB; Maldazys J; Sarna G
    Cancer Treat Rep; 1985 Mar; 69(3):263-7. PubMed ID: 3978656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
    Bates S; Kang M; Meadows B; Bakke S; Choyke P; Merino M; Goldspiel B; Chico I; Smith T; Chen C; Robey R; Bergan R; Figg WD; Fojo T
    Cancer; 2001 Sep; 92(6):1577-90. PubMed ID: 11745237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma.
    Small EJ; Frye JW; Wilkinson MJ; Carroll PR; Ernest ML; Stagg RJ
    Cancer; 1994 Jun; 73(11):2803-7. PubMed ID: 8194022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer.
    Pectasides D; Varthalitis J; Kostopoulou M; Mylonakis A; Triantaphyllis D; Papadopoulou M; Dimitriadis M; Athanassiou A
    Oncology; 1998; 55(1):10-5. PubMed ID: 9428369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of vinblastine plus dipyridamole in advanced renal cell carcinoma. A Hoosier Oncology Group Study.
    Murphy BR; Rynard SM; Pennington KL; Grosh W; Loehrer PJ
    Am J Clin Oncol; 1994 Feb; 17(1):10-3. PubMed ID: 8311000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase Network.
    Haas NB; Giantonio BJ; Litwin S; Minniti CJ; Fox S; Yeslow G; Reilly R; Nahum K; Greenberg R; Halbherr T; Hudes GR
    Cancer; 2003 Nov; 98(9):1837-41. PubMed ID: 14584064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine.
    Braybrooke JP; Vallis KA; Houlbrook S; Rockett H; Ellmén J; Anttila M; Ganesan TS; Harris AL; Talbot DC
    Cancer Chemother Pharmacol; 2000; 46(1):27-34. PubMed ID: 10912574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined treatment with low-dose interferon plus vinblastine is associated with less toxicity than conventional interferon monotherapy in patients with metastatic renal cell carcinoma.
    Tsavaris N; Skarlos D; Bacoyiannis C; Aravantinos G; Kosmas C; Retalis G; Panopoulos C; Vadiaka M; Dimitrakopoulos A; Kostantinidis K; Mitropoulos D; Bougas D; Pantazopoulos D; Kosmidis P
    J Interferon Cytokine Res; 2000 Aug; 20(8):685-90. PubMed ID: 10954911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma.
    Berlin J; King AC; Tutsch K; Findlay JW; Kohler P; Collier M; Clendeninn NJ; Wilding G
    Invest New Drugs; 1994; 12(2):137-41. PubMed ID: 7860231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vinblastine and erythromycin: an unrecognized serious drug interaction.
    Tobe SW; Siu LL; Jamal SA; Skorecki KL; Murphy GF; Warner E
    Cancer Chemother Pharmacol; 1995; 35(3):188-90. PubMed ID: 7805175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of five-day continuous infusion of vinblastine in patients with metastatic renal-cell carcinoma.
    Crivellari D; Tumolo S; Frustaci S; Galligioni E; Figoli F; Lo Re G; Veronesi A; Monfardini S
    Am J Clin Oncol; 1987 Jun; 10(3):231-3. PubMed ID: 3591744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Camptothecin analogues and vinblastine in the treatment of renal cell carcinoma: an in vivo study using a human orthotopic renal cancer xenograft.
    El-Galley R; Keane TE; Sun C
    Urol Oncol; 2003; 21(1):49-57. PubMed ID: 12684128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma.
    Bates SE; Bakke S; Kang M; Robey RW; Zhai S; Thambi P; Chen CC; Patil S; Smith T; Steinberg SM; Merino M; Goldspiel B; Meadows B; Stein WD; Choyke P; Balis F; Figg WD; Fojo T
    Clin Cancer Res; 2004 Jul; 10(14):4724-33. PubMed ID: 15269145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of vinblastine in advanced ovarian carcinoma. A Gynecologic Oncology Group study.
    Sutton GP; Blessing JA; Adelson MD; Hanjani P
    Invest New Drugs; 1990 Nov; 8(4):377-9. PubMed ID: 2084071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.